ADmit Therapeutics is a biotechnology company intended to develop a test for early diagnosis of Alzheimer.
ADmit Therapeutics has raised $6.1M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in July 2023.
ADmit Therapeutics's investors include European Innovation Council, Alzheimer's Drug Discovery Foundation, GENESIS Ventures, Ship2B, Clave Capital.
ADmit Therapeutics is headquartered in Barcelona, Spain.
ADmit Therapeutics is a biotechnology company intended to develop a test for early diagnosis of Alzheimer.
ADmit Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ADmit Therapeutics — Funding & Investors." VCBacked, July 19, 2023, https://www.vcbacked.co/company/admit-therapeutics. Accessed July 19, 2026.
VCBacked. (2023). ADmit Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/admit-therapeutics
{{cite web |title=ADmit Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/admit-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated